Revisions in the International System for Staging Lung Cancer

REFERENCES
1. Gospodarowicz MK, O’Sullivan B, Sobin LH. Prognostic Factors in
Cancer . 3rd Ed. New Jersey: Wiley-Liss, 2006.
2. Brundage MD, Mackillop WJ. Lung cancer. In: Gospodarowicz MK,
O’Sullivan B, Sobin LH, eds. Prognostic Factors in Cancer . 3rd Ed. New
Jersey: Wiley-Liss, 2006:159–163.
3. Sculier JP, Chansky K, Crowley JJ, et al. The impact of additional
prognostic factors on survival and their relationship with the anatomical
extent of disease as expressed by the 6th Edition of the TNM
Classification of Malignant Tumours and the proposals for the 7th
Edition. J Thorac Oncol 2008;3:457–466.
4. Chansky K, Sculier JP, Crowley JJ, et al. The International Association
for the Study of Lung Cancer Staging Project: prognostic factors and
pathological TNM stage in surgically managed non-small cell lung cancer.
J Thorac Oncol 2009;4:792–801.
5. Goldstraw P. History of TNM in Lung Cancer. In: Goldstraw P, ed.
IASLC Staging Manual in Thoracic Oncology . 1st Ed. Florida: EditorialRx,
2009:16–29.
6. Denoix PF. The TNM Staging System. Bull Inst Nat Hyg (Paris) 1952;
7:743.
7. UICC. TNM Classification of Malignant Tumours . 1st Ed. Geneva:
UICC, 1968.
8. Mountain CF, Carr DT, Anderson WA. A system for the clinical staging
of lung cancer. Am J Roentogenol Rad Ther Nucl Med 1974;120:
130–138.
9. UICC. TNM Classification of Malignant Tumours . 2nd Ed. Geneva:
UICC, 1975.
10. American Joint Committee on Cancer Staging and End Results
Reporting. AJC Cancer Staging Manual . 1st Ed. Philadelphia:
Lippincott-Raven, 1977.
11. UICC. TNM Classification of Malignant Tumours . 3rd Ed. Geneva:
UICC, 1978.
12. American Joint Committee on Cancer. Manual for Staging of Cancer.
In: Beahrs OH, Myers MH, eds. 2nd Ed. Philadelphia: JB Lippincott,
1978.
13. Mountain CF. A new international staging system for lung cancer.
Chest 1986;89S:S225–S232.
14. Hermanek P, Sobin LH, UICC. TNM Classification of Malignant
Tumours . 4th Ed. Berlin: Springer Verlag, 1987.
15. American Joint Committee on Cancer. Manual for Staging of
Cancer. In: Beahrs OH, Henson DE, Hutter RVP, et al., eds. 3rd Ed.
Philadelphia: JB Lippincott, 1988.
16. American Joint Committee on Cancer. Manual for Staging of
Cancer. In: Beahrs OH, Henson DE, Hutter RVP, et al., eds. 4th Ed.
Philadelphia: JB Lippincott, 1992.
17. Mountain CF. Revisions in the International System for Staging Lung
Cancer. Chest 1997;111:1710–1717.
18. UICC International Union Against Cancer. TNM Classification of
Malignant Tumours. In: Sobin LH, Wittekind C, eds. 5th Ed. New
York: Wiley-Liss, 1997.
19. American Joint Committee on Cancer. AJCC Cancer Staging
Manual. In: Fleming ID, Cooper JS, Henson DE, et al., eds. 5th Ed.
Philadelphia: Lipincott Raven, 1997.
20. UICC International Union Against Cancer. TNM Classification of
Malignant Tumours . 6th Ed. New York: Wiley-Liss, 2002.
21. American Joint Committee on Cancer. AJCC Cancer Staging Manual .
6th Ed. New York: Springer, 2002.
22. Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer:
Veterans Administration Lung Study Group versus International
Association for the Study of Lung Cancer—what limits limited disease?
Lung Cancer 2002;37:271–276.
23. Goldstraw P. Report on the International workshop on intrathoracic
staging. London, October 1996. Lung Cancer 1997;18:107–111.
24. Goldstraw P, Crowley JJ, Chansky K, et al. The IASLC International
Staging Project on Lung Cancer. J Thorac Oncol 2006;1:281–286.
25. Gospodarowicz MK, Miller D, Groome PA, et al. The process for continuous
improvement of the TNM classification. Cancer 2004;100:1–5.
26. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer
Staging Project: Validation of the proposals for revision of the T, N, and M
descriptors and consequent stage groupings in the forthcoming (seventh)
TNM classification for lung cancer. J Thorac Oncol 2007;2:694–705.
27. Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer
Staging Project: Proposals for the revision of the T descriptors in the
forthcoming (seventh) edition of the TNM classification for lung cancer.
J Thorac Oncol 2007;2:593–602.
28. Rusch VR, Crowley JJ, Giroux DJ, et al. The IASLC Lung Cancer
Staging Project: proposals for revision of the N descriptors in the forthcoming
(seventh) edition of the TNM classification for lung cancer.
J Thorac Oncol 2007;2:603–612.
29. Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer
staging project: a proposal for a new international node map in the
forthcoming seventh edition of the TNM classification for lung cancer.
J Thorac Oncol 2009;4:568–577.
30. Postmus PE, Brambilla E, Chansky K, et al. The IASLC Lung Cancer
Staging Project: proposals for revision of the M descriptors in the forthcoming
(seventh) edition of the TNM classification for lung cancer.
J Thorac Oncol 2007;2:686–693.
31. Goldstraw P, Crowley JJ, Chansky K, et al. The IASLC Lung Cancer
Staging Project: proposals for revision of the stage groupings in the
forthcoming (seventh) edition of the TNM classification for lung cancer.
J Thorac Oncol 2007;2:706–714.
32. Crowley JJ, LeBlanc M, Jacobson J, et al. Some exploratory tools for
survival analysis. In: Lin DY, Fleming TR, eds. Proceedings of the First
Seattle Symposium in Biostatistics: Survival analysis . 1st Ed. New York:
Springer, 1997:199–229.
33. Asamura H, Goya T, Koshlishi Y, et al. How should the TNM staging
system for lung cancer be revised? A simulation based on the
Japanese Lung Cancer Registry populations. J Thorac Cardiovasc Surg
2006;132:316–319.
34. O’Quigley J, Xu R. Explained variation in proportional hazards regression.
In: Crowley J, Ankerst D, eds. Handbook of Statistics in Clinical Oncology .
2nd Ed. New York: Chapman and Hall/CRC Press, 2006:347–363.
35. Shepherd FA, Crowley J, Van Houtte P, et al. The IASLC Lung Cancer
Staging Project: proposals regarding the clinical staging of small-cell
lung cancer in the forthcoming (seventh) edition of the TNM classification
for lung cancer. J Thorac Oncol 2007;2:1067–1077.
36. Vallieres E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer
Staging Project: proposals regarding the relevance of TNM in the pathological
staging of small-cell lung cancer in the forthcoming (seventh)
edition of the TNM classification for lung cancer. J Thorac Oncol 2009;
4:1049–1059.
37. Travis WD, Giroux DJ, Chansky K, et al. The IASLC Lung Cancer
Staging Project: proposals for the inclusion of carcinoid tumours in
the forthcoming (seventh) edition of the TNM classification for lung
cancer. J Thorac Oncol 2008;3:1213–1223.
38. Travis WD, Brambilla E, Rami-Porta R, et al. Visceral pleural invasion:
Pathologic criteria and use of elastic stains: proposals for the
7th edition of the TNM classification for lung cancer. J Thorac Oncol
2008;3:1384–1390.
39. Wittekind C, Greene FL, Henson DE, et al. TNM Supplement: A
Commentary on Uniform Use . 3rd Ed. New Jersey: Wiley-Liss, 2003.
40. Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion classification
in non-small cell lung cancer: a proposal on the basis of outcome
assessment. J Thorac Cardiovasc Surg 2004;127:1574–1578.
41. Berghmans T, Dusart M, Paesmans M, et al. Primary tumour standardized
uptake value (SUVmax) measured on florodeoxyglucose emission
tomography (PDG-PET) is of prognostic value for survival in nonsmall
cell lung cancer (NSCLC): a systematic review and meta-analysis
(MA) by the European Lung Cancer Working Party for the IASLC
Lung Cancer Staging Project. J Thorac Oncol 2008;3:6–12.
42. Goldstraw P. IASLC Staging Handbook in Thoracic Oncology. 1st Ed.
Florida, USA: EditorialRx Press, 2009.
43. Goldstraw P. IASLC Staging Manual in Thoracic Oncology . 1st Ed.
Florida, USA: EditorialRx Press, 2009.
44. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours .
7th Ed. New York: Wiley Liss, 2009.
45. AJCC Cancer Staging Handbook . 7th Ed. New York, Springer, 2009.
46. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac
Cardiovasc Surg 1975;70:606–612.
47. Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung
cancer surgery:proposed definition. Lung Cancer 2005;49:25–33.
48. Lim E, Clough R, Goldstraw P, et al. Impact of positive pleural lavage
cytology on survival in patients undergoing lung cancer resection for
non-small cell lung cancer: an International multicentre meta-analysis.
J Thorac Cardiovasc Surg In press 2009.
49. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy
in stage IB non-small cell lung cancer (NSCLC): update of Cancer
And Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2006;
24[Abstract 7007], 18s.
50. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin
Evaluation (LACE): a pooled analysis of five randomized clinical
trials including 4,584 patients. J Clin Oncol 2006;24[Abstract
7008], 18s.
51. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus Cisplatin
vs Observation in resected non-small-cell lung cancer. N Engl J Med
2005;352:2589–2597.
52. Douillard JY, Rosell R, Delena M, et al. Adjuvant vinorelbine plus
cisplatin versus observation in patients with completely resected stage
IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International
Trialists Association [ANITA]): a randomised controlled trial. Lancet
Oncol 2006;7:719–727.
53. Giroux DJ, Rami-Porta R, Chansky K, et al. The IASLC Lung Cancer
Staging Project: data elements for the prospective project. J Thorac
Oncol 2009;4:679–683.

Read more →

The Future for TNM

The longer term for tnm the 7th edition was primarily based on the
iaslc international database, the bigst databases ever accumulated
for this purpose. the amount of cases recruited was
fifteen to twenty times larger than that that informed any previous
revision. information were donated by forty six sources in over nineteen countries.
the iaslc is grateful for the support offered by colleagues
around the planet, that has ensured the success of
the staging project. though the treatment of those cases
included dissection in 53% of the patients, there have been 30% in
that chemotherapy was used and 29% within which radiotherapy
was utilized. the information were collected from cases treated over
a relatively short episode throughout that the techniques used in
clinical staging were reasonably standardized worldwide. the
recommendations are, for the primary time, intensively
validated. internal validation has ensured that the recommendations
are supported by information from all geographical areas and
across all forms of database. external validation has been established
against the seer database.
there are, but, limitations to the present project. the volume
of information and also the international nature of the information sources
has created information audit extremely tough and, as a result, only
limited checks for consistency are attainable. there are
glaring deficiencies in the worldwide distribution of the information with
no information in the slightest degree being included from africa, south america, or
the indian subcontinent. different vast countries like russia,
china, and that indonesia don't seem to be represented or just poorly represented.
though less surgically dominated than previous
databases, the spread of treatment modalities doesn't reflect
the observe in most establishments. the episode underneath study predates
the widespread and routine use of pet scanning, which
has had an monumental impact on clinical staging algorithms.
in an exceedinglyny retrospective database, one has to gather the information that
were thought of necessary by every supply and this reflects the
use for that the information were collected. though we've got an
monumental quantity of information on a few descriptors, like tumor
dimension, we've got too very little on several to prove or disprove the
validity of a few descriptors.
it's hoped that our colleagues in clinical observe can recognize
that the changes instructed by this project are driven by
the information offered to us from a database of over 68, 000 cases.
even with the acknowledged limitations of the database, its
breadth has allowed the application of evidence-based standards
in terms of statistical power, reliability, and scientific validity
that were not attainable in previous revisions. inevitably,
existing treatment algorithms are going to be challenged however it's hoped
that by the rigorous analysis of massive volumes of information, the utility
of the tnm classification for lung cancer are going to be strengthened.
the iaslc staging project is currently getting into its next
phase. this may see the scope of the project expand to include
neuroendocrine tumors, together with carcinoid tumors, mesothelioma,
and possibly different thoracic malignancies. a prospective
information set has been established and web-based information collection has
been trialed. 53 we hope that these features can ensure additional,
rigorously validated proposals regarding thoracic malignancies
for the 8th edition of the tnm classification of malignant
tumours and beyond. any institution that wishes to contribute
will receive further info by sending an email to information@
crab. org with the phrase “iaslc staging project”
within the subject line. the success of subsequent cycle of revision, as
during this cycle, totally depends on the support we receive from
the worldwide lung cancer community.
the tnm classification of malignant tumours has stood the
take a look at of time and remains the foremost powerful prognostic tool
in lung cancer. four the iaslc staging project created robust
proposals for the 7th edition and also the resultant 7th edition of
tnm classification of malignant tumours, that additional accurately
correlates the anatomical extent of disease and prognosis.
in the longer term, the challenge are going to be to integrate tnm with
different prognostic factors because they are identified and validated.

Read more →

Clinical Implications of the 7th Edition

Clinical implications of the 7th edition intensive
validation formed a central feature of the iaslc staging
project leading to robust changes for the 7th edition of tnm
classification of malignant tumours. but, it's recognized
that a number of these changes can produce issues for colleagues
during this field. the necessity to sacrifice backward compatibility
with existing databases within the search for a staging system,
that is manageable in clinical observe, has already been
mentioned. it could be also recognized that moving a few descriptors
among stage categories and recommending the proposed
changes to the stage groupings can cut across established treatment
algorithms. the moving of the massiver, node-negative t2
tumors ( t2b cases quite five cm in greatest dimension ) and
tumors quite seven cm in greatest dimension ( that would
become t3 ) from stage ib into stage iia and stage iib, respectively,
can clearly raise the question on whether or not such cases
ought to have adjuvant chemotherapy once complete resection.
though there's still doubt on the price of adjuvant chemotherapy
once complete resection for node-negative cases in
stage ib, 49, 50 a minimum of 2 giant trials have shown a profit for
node-positive cases in stages ii and that iiia. 51, 52 the question as
to whether or not these larger, node-negative tumors profit from adjuvant
therapy once complete resection can no more than be resolved by
giant, prospective randomized trials. the reassignment of cases
with further nodules in an exceedinglyn ipsilateral, nonprimary bearing
lobe into a t4 descriptor instead of an m1 descriptor and
the relocation of t4 n0 m0 and t4 n1 m0 cases into stage
iiia also will result in queries on the appropriate treatment
algorithm. one limitation of our database was that it doesn't
enable us to be sure whether or not this reassignment could be appropriate
for cases with multiple further tumor nodules or for
all t4 cases. multimodality treatment models, a few including
dissection, can no doubt evolve, informed by appropriate trials.
in alternative things, the changes included within the 7th edition
of the tnm classification of malignant tumours higher reflect
current observe as with the move of cases with malignant pleural
effusions into an m class from a t class. within
the iaslc database, there was a transparent distinction in prognosis
between patients with metastases to the contralateral lung or
related to a pleural effusion and people with metastases at
distant sites outside the thorax. in general, the latter have the
worst prognosis and are traditionally thought-about as stage
iv, and maydidates for primarily systemic treatment. it therefore
appears relevant to subclassify, among an expanded stage iv,
those cases with spread among the thorax as m1a and people
with metastases to distant sites as m1b.

Read more →

PROPOSALS FOR TESTING MALIGNANT TUMOURS

Proposals for testing the tnm classification of malignant
tumours allows for the formulation of “proposals for testing. ”
this section is largely aspirational allowing additional
classifications to be trialed for a few years. usually, these have
been instructed by inquiries to the uicc tnm helpdesk or in
revealed studies scrutinized by their systematic annual literature
search. for a few, there may be already supportive information, except for
all, extra information and validation are needed before considering
their inclusion into future revisions. within the 7th edition, these
proposals embody the following :
one. where the pn0 class has been based mostly on but the
recommended variety of lymph nodes ( six lymph nodes/
stations, 3 mediastinal, as well as the subcarinal nodes
#7, and 3 n1 ) or where the very best node removed
contains metastases, it's proposed that the resection be
categorized as an “ uncertain resection, ” and designated
“ r0( un ). ” 47
a pair of. the concept of nodal zones has been instructed as a straightforwardr,
additional utilitarian system for clinical staging where surgical
exploration of lymph nodes has not been performed. 28
an exploratory analysis instructed that nodal extent could
be grouped into 3 categories with differing prognoses :
( a ) involvement of one n1 zone, designated as n1a,
( b ) involvement of over one n1 zone, designated as
n1b, or one n2 zone, designated n2a, and ( c ) involvement
of over one n2 zone, designated as n2b. it's
instructed that radiologists, clinicians, and oncologists use
the classification prospectively, where additional detailed information on
nodal stations isn't obtainable, to assess the utility of such a
classification for future revision.
three. a recent metaanalysis 48 has confirmed that pleural lavage
cytology ( plc ), undertaken immediately on thoracotomy
and shown to be positive for cancer cells, has an adverse
and that independent prognostic impact following complete
resection. such patients could also be candidates for adjuvant
chemotherapy. surgeons and pathologists are encouraged
to undertake this easy addition to intraoperative staging
and collect information on plc+ve and plc− ;ve cases. where
the resection fulfils all of the requirements for classification
as a “complete resection, ” r0 other then plc has been performed
and that is positive the resection ought to be classified as
“ r1( cy ). ”
four. a regularized definition of visceral pleural invasion
( vpi ) has been incorporated into the 7th edition of tnm
classification of malignant tumours. 38 a subclassification
has been proposed employing a “pl” class be used to explain
the trailological extent of pleural invasion :
pl0 tumor inside the subpleural lung parenchyma or
invades superficially into the pleural connective tissue
beneath the elastic layer
pl1 tumor invades beyond the elastic layer
pl2 tumor invades to the pleural surface
pl3 tumor invades into any part of the parietal
pleura
five. there are suggestions that the depth of chest wall invasion
could influence prognosis following resection of lung cancer.
a subclassification has been proposed, based mostly on the histopathologic
findings of the resection specimen, dividing such
pt3 tumors into pt3a if invasion is limited to the parietal
pleura ( pl three ), pt3b if invasion involves the topothoracic
fascia, and pt3c if invasion involves the rib or soft tissue.
six. imaging proof of lymphangitis carcinomatosa is sometimes
a contraindication to surgical treatment. the “l” class,
that is employed to assess pathological proof of “lymphatic
invasion, ” is that therefore not applicable. the radiological extent
of lymphangitis is thought to be of prognostic importance.
an exploratory analysis of this feature is proposed employing a
“cly” class during which cly0 indicates that radiological evidence
of lymphangitis may be absent, cly1 indicates lymphangitis
is present and confined to the space round the primary
tumor, cly2 indicated lymphangitis at a distance from the
primary tumor other then confined to the lobe of the primary, cly3
indicates lymphangitis in alternative ipsilateral lobes, and cly4
indicates lymphangitis affecting the contralateral lung.
seven. all cases during which there's metastatic spread to distant organs
are classified as m1b disease. but, there are clear
differences in prognosis based mostly on tumor burden and also the
essential nature of a few organ sites. such differences will
influence the selection of treatment and also the intent of treatment
by all modalities of care. selected patients with isolated
metastases to one organ could also benefit from surgical
treatment. information on m1b cases ought to record the quantity
of metastases and also the variety of metastatic sites as so much as is
practicable. it ought to prove feasible during all cases to record if
metastases are single or multiple.
eight. the categories assigned to cases during which there are additional
tumor nodules of similar histological appearance within the lung( s )
has been reclassified within the 7th edition of tnm classification
of malignant tumours. we willnot verify that this is often valid
for cases during which multiple deposits are encountered and prospective
information collection is necessary to totally validate this reclassification.
it's recommended that the quantity of nodules
within the lobe of the primary, alternative ipsilateral lobes and also the contralateral
lung, and also the diameter of the bigst deposit in each
location be documented as so much as is practicable.
nine. bronchopulmonary carcinoid tumors are included within
the 7th edition of tnm classification of malignant tumours.
but, more information are required to assess the prognostic
impact of bound features in carcinoid tumors ; typical versus
atypical features, t size cut points, the prognostic impact of
multiple deposits, and whether or not these are related to the
syndrome of diffuse idiopathic pulmonary neuroendocrine
cell hyperplasia ( dipnech ). during addition, in carcinoid tumors,
long-term survival is expected even when associated
with multiple tumor nodules or nodal disease. it is that therefore
vital to gather information on disease-specific survival
ten. pet scanning using eighteen f-fluorodeoxyglucose ( fdg ) is
currently widely utilized and has had an impact of the accuracy
of clinical staging and referrals for surgical treatment.
during addition, a metaanalysis has shown that pet features,
like the maximum price of the suv max within the primary
tumor prior to treatment may be an freelance prognostic
issue. forty one where pet scans are performed, it's suggested
that information is collected on features like suv max within the
primary and any nodal and/or metastatic sites.
we encourage clinicians, radiologist, nuclear medicine
specialists, and pathologists to gather information on these aspects of
lung cancer staging for subsequent analysis.

Read more →

ADDITIONAL CHANGES IN THE 7TH EDITION OF TNM CLASSIFICATION OF MALIGNANT TUMOURS

The additional
proposals, advised by analyses inside the iaslc staging
project, have all been incorporated into the 7th edition of
tnm classification of malignant tumours, together with clarification
on alternative aspects of the classification. these embrace the
following :
one. the “iaslc” nodal chart and therefore the accompanying table
of definitions has been accepted because the recommended
means that of describing the regional lymph node involvement
for lung cancers. it is additionally recommended that a minimum of six
lymph nodes/stations be removed/sampled and confirmed
on histology to be free of disease to confer pn0 standing.
3 of those nodes/stations ought to be mediastinal, including
the subcarinal nodes ( #7 ) and 3 from n1
nodes/stations.
a pair of. there's bigger emphasis on the use of the tnm classification
in sclc.
three. bronchopulmonary carcinoid tumors are, for the primary time,
coated by the tnm classification.
four. the definition of visceral pleural invasion is included within
the tnm classification.
five. in cases during which there's over one tumor within the
lung( s ), the distinction between metastases and multiple
synchronous primary tumors has traditionally been based
on the martini and melamed forty six paper. within the 7th edition,
these definitions are retained other then supplemented by a
brand new
emphasis on the role of the trailologist, utilizing where
necessary special studies like immunohistochemistry
and molecular markers. during this distinction, lung differs
from alternative organ sites as extra tumor nodules that are
microscopic or otherwise solely discovered on pathological
examination are too coated within the classification.
six. within the application of the “v” classification, lung too differs
from alternative organ sites as, in lung, invasion of arterioles
isn't uncommon. the v classification in lung therefore
c overs vascular invasion, whether or not venous or arteriolar.

Read more →

THE 7TH EDITION OF TNM IN LUNG TUMORS

The recommendations from the iaslc staging project were
submitted to the uicc and ajcc on time, underwent internal
review, and were accepted while not modification because the 7th
edition of tnm in lung and pleural tumours. thanks to the
central role of the iaslc staging project within the creation of
the 7th edition and delays within the publishing schedules of the
uicc and also the ajcc, the iaslc was accorded the privilege
of being the primary to publish this new classification, at the 13th
world conference on lung cancer in an exceedinglyugust 2009. 42, forty three the
7th editions of this classification were subsequently published
later in 2009 by the uicc and ajcc. 44, 45 the t, n, and
m descriptors are listed in table thirty. four and also the resultant stage

Read more →

EXTRA PROGNOSTIC FACTORS SUBCOMMITTEE

Recommendation : invasion of the visceral pleura ought to be
defined as “invasion beyond the elastic layer together with invasion
to the visceral pleural surface. ” the use of elastic stains is recommended
when this feature isn't clear on routine histology.
i ) extra prognostic factors subcommittee 3
there could be a growing debate on how extra prognostic
factors ought to be integrated with the tnm classification. as
advised earlier, a number of these can have prognostic importance
and others are predictive of response to treatment. ultimately,
the uicc and ajcc should decide whether or not such factors are incorporated
among tnm or, as appears a lot of probable, are added
to tnm during a composite prognostic model. the iaslc database
contained limited data of patient-related factors like
age, gender, and performance standing ; tumor-related factors such
as cell type and alittle of differentiation ; and laboratory variables
like serum albumen, hemoglobin, white blood cell count, and
sodium. an analysis of the price and that interaction of those variables
with tnm stage in clinically and pathologically staged cases on
nsclc was undertaken and also the results were printed. three, 4
we failed to collect knowledge on positron emission tomography
( pet ) studies other then a metaanalysis, primarily based on a literature review,
was undertaken by the european lung cancer study party in
collaboration with the iaslc staging project. this showed
the prognostic significance of the pet maximum standardized
uptake price ( suv max ) within the primary tumor at diagnosis forty one to
be an freelance prognostic think about lung cancer.

Read more →

SOLELY PERFORATION OF THE MESOTHELIUM

To our recommendations for the 7th edition. in spite of this, pathologists
have struggled to arrive at an internationally agreed definition
of such invasion. the uicc states within the tnm supplement :
a commentary on uniform use 39 that “invasion of visceral pleura
( t2 ) includes not solely perforation of the mesothelium other then also
invasion of the lamina propria serosae” though the japan lung
cancer society solely considers that “p2, ” defined as “tumor that
is exposed on the pleural surface other then doesn't invade adjacent
anatomic structures” is by itself a t2 descriptor. forty the iaslc
staging project has undertaken a literature review of this subject
and has proposed a regularized definition

Read more →

RECOMMENDATION : RECLASSIFY TUMORS BY MALIGNANT PLEURAL OR PERICARDIAL EFFUSION

Recommendation : reclassify tumors by malignant pleural
or pericardial effusion as m1 disease.
c ) n descriptors subcommittee 28
this subcommittee studied the prognostic significance of
the nodal categories within the 6th edition and located that the current
n0 to n3 descriptors defined distinct prognostic groups
for each clinical and pathologic staging. they undertook exploratory
analyses on the prognostic impact of individual
nodal stations within the hilum and mediastinum, and combinations
and permutations of cell type, lobe of the primary, patterns
of nodal involvement in n1 and n2 locations, and therefore the
impact of “skip” metastases to the mediastinal nodes without
hilar node disease. though these analyses showed a few interesting
results, the teams were little and compromised geographically
and by treatment modality. they concluded that
any prospective studies were necessary before taking these
suggestions forward. such studies would be facilitated by an
agreed set of international definitions for nodal stations, and
a
brand new “iaslc” international nodal chart, that, for the primary
time, might reconcile the differences between the japanese
nodal chart and therefore the mountain/dressler chart. the concept of
“nodal zones” was prompt, amalgamating nodal stations into
larger units among the anatomical region. it had been hoped that
this would ensure that nodal mapping was relevant to oncologists
and radiologists used to handling bulky disease that
usually transgressed the boundaries of adjacent nodal stations.
recommendation : the existing categories of n0 to n3
ought to be retained for the 7th edition. an iaslc nodal chart
was created, incorporating the concept of nodal zones. 29
d ) m descriptors subcommittee 30
an analysis of these cases prompt for reclassification as
m1 caused by malignant pleural effusion showed the same survival
to those classified as m1 within the 6th edition due to
extra tumor nodules within the contralateral lung. these two
teams had a stronger survival than that of cases classified within the
6th edition as m1 by the presence of distant metastases, by a
little however significant distinction.
recommendation : reclassify m1 due to additional
tumor nodules within the contralateral lung as m1a. reclassify t4
tumors caused by malignant pleural or pericardial effusions
as m1a. reclassify m1 caused by distant metastatic disease
as m1b.
e ) changes to the tnm stage groupings within the 7th
edition 31
this aspect of the project raised problems that affected the
means that the recommendations derived from the t, n, and m
descriptor subcommittees were presented in the ultimate documents.
where analysis prompt that new descriptors were
necessary to accommodate patients whose prognosis differed
from the opposite cases among any explicit t or m class,
2 different strategies were thought of : ( a ) retain that descriptor
within the existing class, identified by alphabetical subsets.
as an example, extra pulmonary nodules within the lobe
of the primary, thought of to be t4 within the 6th edition, would
stay t4 however identified as t4a, whereas extra pulmonary
nodules in alternative ipsilateral lobes, designated as m1 in
the 6th edition, would become m1a. ( b ) enable descriptors to
move between categories, to a class containing alternative descriptors
with the same prognosis, as an example, extra pulmonary
nodules within the lobe of the primary would move from
t4 to t3, and extra pulmonary nodules in alternative ipsilateral
lobes would move from m1 to t4. the primary strategy had
the advantage of allowing, to an outsized extent, retrograde compatibility
with existing databases. unfortunately, this strategy
generated an outsized range of descriptors ( approximately twenty )
and an impractically massive range of tnm subsets ( 180 ).
for this reason, backward compatibility was compromised
and strategy b was preferred for its clinical utility. the recommendations
were so formatted as previously described.
these changes to t and m descriptors were then incorporated
into the resultant tnm subsets. atiny low range of candidate
stage grouping schemes were developed initially, based mostly on a
“training” set, employing a recursive partitioning and amalgamation
( rpa ) algorithm. 32 this generated a tree-based model
for the survival information using log-rank take a look at statistics for recursive
partitioning and, for choice of the necessary groupings,
bootstrap resampling to correct for the adaptive nature of the
splitting algorithm. an ordered list of groupings from the terminal
nodes of the “survival tree” was created, and with this
as a guide, many proposed stage groupings were created by
combining adjacent teams. choice of a final stage grouping
proposal from among the candidate schemes was based mostly on
its statistical properties within the coaching set and that its relevance to
clinical follow, and was arrived at by consensus.
the survival of cases among our database stratified by the
6th edition of tnm classification of malignant tumours and
by the iaslc proposals for the 7th edition are shown for cases
staged clinically in figure thirty. three and for pathologically staged
cases in figure thirty. four. the proposed system higher delineated
the first stage cases, where issues with overlap between
ib and that iia are noted with the 6th edition of tnm
classification of malignant tumours. thirty three improvement was also
seen within the distinction between clinical iia and that iib, furthermore as
the proportion of cases assigned to stage iia, another weakness
of the 6th edition of tnm classification of malignant
tumours. for each the clinical and pathological stage models,
there was a rise within the price for r two, an estimate of the
% variance explained ( pve ) by the model. thirty four the proposals
for the 7th edition created use of well-justified changes
to t and m, and served to determine subsets of patients with tumors
of totally different sizes with differing prognoses. each the proposed
new system and therefore the 6th edition of tnm classification
of malignant tumours showed a reversal on pathological staging
from the expected survival for advanced stage disease ( iiib
and that iv ). this result, though anomalous, may be explained
by the selective nature of advanced cases undergoing dissection,
several of that were taken to dissection on the assessment that
their disease was limited just to be discovered to own advanced
disease at thoracotomy.

Read more →

CLASSIFICATION OF MALIGNANT TUMOURS

A ) validation and methodology subcommittee 26
all exploratory analyses were examined for his or her relevance
within the clinical/evaluative, ctnm population and therefore the postsurgical/
pathological ptnm population. there was ctnm knowledge on
53, 640 cases, ptnm on thirty three, 933 cases, and each c and p tnm
in twenty, 006 cases. the recommendations of the t descriptors
subcommittee were assessed in m0 cases with all combinations
of n class and completeness of resection, r, class.
internal validation of the recommendations was checked for
consistency across all geographical areas and between differing
forms of knowledge supply. where the volume of knowledge permitted,
within the t descriptors and therefore the tnm stage grouping analysis,
the recommendations were created employing a “training set” of a
randomly selected subgroup comprising 2 thirds of all cases
and therefore then validated against the opposite one third of cases within the
“validation set. ” external validation was mainly established by
studying the appropriateness of all recommendations against
the surveillance, epidemiology, and finish results ( seer ) database
for 1998 to twenty00. consistency with suggestions raised in
the literature was undertaken in collaboration with the uicc
literature watch program.
b ) t descriptors subcommittee 27
there was a paucity of knowledge on several t descriptors.
in spite of this,dge knowle on tumor size was well represented inside the
database. a running log-rank analysis of size as a continuous
variable in t1 tumors revealed a big cut purpose at a pair of cm.
when tested within the validation subset, there was a statistically
significant distinction in survival between t1 tumors up to
a pair of cm in size compared with those over a pair of cm however not
over three cm.
recommendation : t1 tumors ought to be subclassified as
t1a for tumors up to a pair of cm in size and t1b tumors for those that
are over a pair of cm in size however not bigger than three cm in size.
the same analysis of size in larger tumors showed 2 additional
cut points, one at five cm and another at seven. three cm. for clinical
utility, the latter was taken as seven cm. using these cut points,
3 extra size groupings were identified within the training
set ; those patients whose tumors were larger than three cm however not
over five cm in size, those with tumors over five cm in
size however not over seven cm in size, and people whose tumors
were over seven cm in size. when the survival of those groups
was assessed within the validation subset, there have been distinctly different
survival curves for every cluster. furthermore, survival of
those with the bigst tumors, larger than seven cm in size, was
similar to cases classified as t3 by alternative criteria.
recommendation : t2 tumors ought to be subclassified into
t2a tumors, over three cm in size however not over five cm,
and t2b tumors, over five cm however not over seven cm in
size. tumors over seven cm in size ought to be reclassified as
t3 tumors.
when the survival of cases classified by the 6th edition of
tnm classification of malignant tumours as t4 on the idea of
extra tumor nodules within the lobe of the primary was compared
with that of cases classified as t3 or t4 by alternative criteria,
the survival of the previous was found to be totally different to that of
t4 tumors however similar to that of t3 tumors.
recommendation : reclassify t4 tumors by additional
nodules within the lobe of the primary tumor as t3.
similarly, the survival of cases with extra tumor
nodules in ipsilateral lobes alternative than that of the primary
tumor, classified as m1 within the 6th edition of tnm classification
of malignant tumours, compared with t4 and m1 cases by
alternative criteria, was in line with t4 cases and abundant higher than
alternative m1 cases.
recommendation : reclassify m1 tumors by additional
nodules in alternative ipsilateral lobes ( alternative than the lobe of the
primary tumor ) as t4.
cases classified by the 6th edition of tnm classification
of malignant tumours as t4 by the presence of a malignant
pleural effusion had a survival that was abundant worse than t4
tumors and similar to that of m1 cases.

Read more →

THE IASLC STAGING PROJECT

At the 8th world conference on lung cancer in dublin in
1997, the board of the iaslc thought of a submission from the
late dr. rj ginsberg and dr. p goldstraw to form an international
staging committee. the board agreed that the iaslc, as
the no more than international organization dedicated to the study of lung cancer,
representing all clinical and analysis aspects of lung cancer
care, had a responsibility to become concerned within the revision process
and to develop a replacement database to inform future revisions. at
its next meeting in december 1998, the board agreed to supply
pump-priming funds for such a project. conferences were held in
london in 1999 and 2000, throughout that the composition of
the committee was developed to ensure speciality and geographical
representation and also the involvement of stakeholders like
the uicc, the ajcc, and also the joint japanese societies involved
within the study of lung cancer. at following world conference in
2000, collaboration was established with colleagues from cancer
analysis and biostatistics ( crab ), a not-for-profit medical statistics
and information management organization primarily based in seattle with
in depth expertise with multicenter information collection and analysis.
at that meeting, sufficient funds were guaranteed from the
pharmaceutical trade to enable a significantvictory.

"the syrian regime has meeting in london in
2001, to that database proprietors were invited to present an
outline of the information they held. over the 2-day workshop, information on
eighty, 000 cases were presented from twenty databases across the globe.
in was set to estimate the budget primarily based on the assumption
that thirty, 000 suitable cases may be recruited which the length
of the project would be the 5-year cycle used by the uicc and
ajcc at that point. cases would be solicited from databases
worldwide, treated by all modalities of care, between 1990 and
2000, a episode throughout that there had been relative stability in
staging strategies. this would ensure a 5-year follow-up by the
time of study. in collaboration with crab, the information fields and
information dictionary were finalized. later that year, full funding was
obtained by the iaslc via a vicinitynership agreement with the
pharmaceutical trade.
conferences continued to be held on an annual basis utilizing
the globe conferences, currently held biennially, wherever potential.
the uicc was well awake to the got to update the revision
method and, around now, established a “tnm process
subcommittee. criteria were established for instituting changes
to the tnm classification and for the analysis of proposals
for such changes. ” 25 a system for continuous monitoring of the
proposals within the literature, a “literature watch, ” was established. for
every cancer type, a “tnm skilled panel” was established to review
the sifted literature and facilitate within the analysis of proposals
for modification. in might 2003, the uicc and ajcc extended the
revision cycle to seven years, that resulted in publication of the 7th
edition of the tnm classification of malignant tumours being
deferred till 2009. the internal review processes among these
organizations needed that the iaslc submitted its proposals
to the uicc in january 2007 and also the ajcc in june 2008.
information collection was discontinued in an exceedinglypril 2005, by which
time, over 100, 000 cases had been submitted to the information center
at crab. once an initial sift, that excluded cases with insufficient
information on stage, treatment, or follow-up, cases outside
the planningated study episode and cases within which the cell type
was unsuited or unknown 81, 015 were out there for analysis,
67, 725 cases of nsclc, and thirteen, 290 cases of sclc. the proposals
for the 7th edition of tnm classification of malignant
tumours were formulated on the nsclc cases alone. the geographical
distribution of the information sources during this cell type is
illustrated in figure thirty. one and also the spread of treatment modalities
is shown in figure thirty. a pair of. this huge task was divided
among subcommittees, every charged with collaborating with
crab to research the information and develop proposals for given aspects
of the study. these lined the t, n, and m descriptors,
the relevance of tnm in sclc and that in carcinoid tumors, the
development of an internationally agreed nodal chart, and a
thorough review of the worth of further prognostic factors
and biological markers. as validation had been a difficulty with
previous revisions, a separate subcommittee was created to undertake
a comprehensive validation method and to ensure that
revisions were compatible with the strategyology of the uicc
and ajcc. this committee was closely concerned with the work
of the opposite teams because their proposals evolved

Read more →

THE NEED FOR CHANGE AMONG LUNG CANCER CLINICIANS

Undoubtedly, the lung cancer community owes an enormous
debt of gratitude to the pioneers of tnm, particularly to dr.
clifton mountain. but, over the last decade, there has
grown a feeling among lung cancer clinicians and scientists that
changes were required to the method for revision of the tnm
classification for lung cancer. the mountain database, which
had been the major supply of knowledge to inform revisions of the
tnm system up to and that including the 6th edition had, by
1996, enlarged to embody 5319 cases. therefore, it had been a relatively
tiny database, accumulated over twenty years, throughout that period
several advances had been created within the techniques on the market for
pretreatment staging, most noticeably the routine application
of computed tomography ( ct ) scanning. the nice majority
of cases during this database had been referred for surgical treatment
and had been recruited from one center. there have been
understandable considerations on whether or not the recommendations
emanating from such a database were traditionally valid, globally
relevant, and appropriate for evaluating treatment by nonsurgical
or combined modality care. oncologists treating tiny cell
lung cancer ( sclc ) had abandoned tnm for all, except those
terribly limited cases during which dissection was thought-about and that instead
were using an easyr classification based mostly on the single distinction
between “limited” or “extensive” disease. 22 even when
used in a very surgical setting and for nslc, the dearth of validation
in previous editions of the tnm classification of malignant
tumours had led to several of the descriptors being increasingly
challenged. knowledge had been revealed suppor ting size cutoffs
different than the 3-cm limit separating t1 and t2 tumors, ranging
from but one cm to quite nine cm. “irresectable” t4
tumors had been resected with smart results in selected cases.
the descriptors applied to cases during which there have been additional
tumor nodules within the lobe of the primary and different ipsilateral
lobes were usually regarded as harsh. oncologists had long
treated cases with pleural effusion, the “wet” iiib cases, with
the therapeutic strategies used for patients with metastatic,
stage iv disease. clearly, if the tnm classification was to retain
its central role within the day-to-day care of patients with lung
cancer in a veryn evidence-based era, its recommendations had to be
intensively validated and the method for amendment had to be modernized
to form the staging system fit for purpose. these concerns
crystallized at an international association for the study
of lung cancer ( iaslc ) workshop on “intrathoracic staging”
held at the brompton hospital in london in october 1996. 23
one in all the revealed recommendations of this meeting was
“the establishment by the iaslc of a staging committee

Read more →

THE HISTORY OF TNM IN LUNG CANCER

The resultant tnm subsets were grouped into stages i to iii.
four of the attainable eighteen tnm subsets had too few cases
for analysis and seven others contained but 100 cases.
survival curves showed distinct differences between prognosis
in overall t, n, and m categories and also the three-stage groupings
to five years and beyond. a table showed the differing survival
at twelve and eighteen months for those tnm subsets for that data
was offered. no assessment of statistical significance was presented,
and also there was no validation of the individual descriptors.
these proposals were incorporated within the 2nd edition
of the uicc tnm classification of malignant tumours published
in 1975 nine and also the 1st edition of the manual for staging
of cancer revealed by the ajc in 1977. 10
the 3rd edition of the uicc manual, revealed in
1978 11 and revised in 1982, any divided stage i into ia and
ib ( note that at that point, stage subgroups were lowercase ) and
established stage iv for cases with m1 disease. the “x” descriptor,
erratically applied to a few categories in earlier editions,
was, for the primary time, introduced as an choice in a veryll three
categories of t, n, and m.
the yankee committee, currently the ajcc, failed to make
these changes in its 2nd edition, that was revealed in
1983. 12
by 1986, dr. mountain had assembled a replacement database containing
3753 cases of lung cancer with a minimum follow-up
of a pair of years. the proposals from this supply were accepted by the
ajcc, and subsequently by the uicc and maycer committees
in germany and japan, making “a new international staging
system for lung cancer. ” thirteen the recommendations were published
within the 4th edition of the uicc tnm classification of
malignant tumours in 1987 fourteen and that in the 3rd edition of the
yankee manual in 1988. fifteen changes proposed during this edition
embrace the addition of “visceral pleural invasion” as a t2
descriptor, the lookation of superficial tumors limited to the
bronchial wall as t1 irrespective of location, a recommendation
that the occasional pleural effusion that was cytologically negative
may be ignored in defining the t class, the reemergence
of the t4 class, and also the creation of an n3 class.
the existing t3 descriptors were split between t3 and also the new
t4 class on the premise that the previous would retain those descriptors
that indicated that such tumors were “candidates for
complete resection, ” whereas the latter would be “inoperable. ”
the previous descriptor of mediastinal invasion was split into
its part parts, with invasion of the mediastinal pleura or
pericardium remaining t3, whereas invasion of the good vessels,
heart, trachea, esophagus, carina, and vertebral bodies became
t4 descriptors, at the side of the presence of a pleural effusion.
the situation was confused by further definitions of t3 and
t4 given within the text. those tumors with “limited, circumscribed
extrapulmonary extension” were to be retained at intervals the t3
class, whereas those with “extensive extrapulmonary extension”
became t4. these conflicting definitions resulted in a very lack
of clarity on whether or not tumors invading such structures because the
pericardium remained t3 if there was in depth invasion and
were thought-about inoperable or became t4, or if invasion limited
to a circumscribed space of the esophagus and resected completely
at operation ought to be thought-about to be t3 or t4. metastases to
the ipsilateral mediastinal nodes and subcarinal nodes remained
at intervals the n2 class, and also the new n3 class was added to
accommodate metastases to the contralateral mediastinal nodes,
contralateral hilum or ipsilateral, and contralateral supraclavicular
or scalene lymph nodes. further changes in that edition
embrace the moving of t1n1m0 cases from stage i to stage ii
and also the division of stage iii into iiia ( containing t3 and n2
cases ) and that iiib ( containing t4 and n3 cases ). once once more, a
table showed the differing survival prospects for tnm subsets,
and a graph showed statistically significant survival differences
between stage groupings. no validation was presented for the
individual descriptors or to substantiate the movement of some
into t3 and others t4.
the ajcc created no changes within the classification for lung
cancer in its 4th edition revealed in 1992. 16
at the time of consequent revision in 1997, the database of
dr. mountain has increased to embrace 5319 cases, all other then 66
being nsclc, 4351 cases treated at the md anderson cancer
center between 1975 and 1988, and 968 cases referred there from
the national cancer institute cooperative lung cancer study
cluster for confirmation of stage and histology. seventeen tables showed
statistically significant differences in survival as way as five years
between clinical/evaluative ctnm categories and pathological/
postsurgical ptnm categories t1n0m0 and t2n0m0 and
these were divided into a replacement stage ia and stage ib, respectively.
similarly, t1n1m0 cases were placed in a very new stage iia, and
t2n1m0 and t3n0m0 cases became stage iib. the remaining
tnm categories in stages iiia, iiib, and that iv remained unchanged
though statistically significant differences were found
between a few tnm categories. a further paragraph determined
that “the presence of satellite tumor( s ), not lymph nodes,
at intervals the primary-tumor lobe of the lung ought to be classified as
t4. intrapulmonary ispilateral sic metastasis in a very distant, that's,
nonprimary lobe( s ) of the lung, ought to be classified m1. ” seventeen no
information was presented to support these suggestions and also the wording
used to explain such further pulmonary nodules was loaded
to underline the apparent logic of considering a few to be “satellite”
lesions and, so, a t descriptor, whereas those in other
lobes were a “metastasis” and, so, an m descriptor.
these recommendations were accepted by the ajcc and
the uicc-tnm prognostic factors project committee and
appeared within the 5th edition of their publications in 1997. eighteen, 19
there have been no changes within the lung cancer classification in
the 6th edition of tnm classification of malignant tumours
revealed in 2002. a pair of

Read more →

THE INTERNATIONAL STAGING SYSTEM FOR LUNG CANCER

Over the last forty years, the international staging system
( iss ) has become an essential tool for all those concerned in
the care of patients suffering from cancer or undertaking
analysis during this field. increasingly, patients are getting
empowered by understanding this system and are making
use of this knowledge within their search for information
within the literature, on the net, and that in discussions with
their medical advisors. at the guts of the iss lies an international
shorthand that utilizes the tnm-based system
to explain the anatomical extent of the disease : the
t class describing the dimensions and extent of the primary
tumor, the n class describing the extent of involvement
of regional lymph nodes, and also the m class describing
the presence or absence of distant metastatic spread. each
class is defined by ascending numerical descriptors that
indicate increasingly advanced disease. all attainable combinations
of the t, n, and m categories are then used to
produce tnm subsets. tnm subsets with similar prognoses
are then combined into stage groupings. the term stage,
while not more classification, relates to the pretreatment,
clinical stage or ctnm. this is often derived using the evidence
offered from clinical history and examination, blood tests,
imaging, endoscopic examination, biopsy material, surgical
examination, and the
other check thought of necessary prior
to creating a
call on the appropriate treatment during any
individual. if this call ends up in surgical treatment, then
extra info becomes offered at dissection and by
pathological examination allowing a additional correct assessment
of disease extent, the trailological, postsurgical stage
or ptnm. this doesn't replace the ctnm, that should
stay as a record within the patient’s notes. if the patient undergoes
preoperative, “induction” therapy, typically with
chemotherapy and/or radiotherapy, then a reassessment is
created when this treatment, prior to a final call on surgical
treatment. the proof offered from this method is
used to make the yctnm, and when surgical treatment in
these circumstances, the postsurgical pathological extent of
disease is described as yptnm. at varied points within the patient’s
journey, events might enable or demand a reassessment
of disease extent. an rtnm is also established if relapse
occurs when a disease-free interval. an atnm is also formulated
if the disease is 1st discovered at an autopsy. in
every case, previous assessments of tnm are retained within the
patient records.
the tnm classification could be administered by 2 nongovernmental
bodies : the yank joint committee on cancer
( ajcc ) and also the union internationale contre le cancer
( uicc ) currently stated by the anglicized type of its title, the
international union against cancer. every produces its own
publication on cancer staging, denoted as a cancer staging
manual by the ajcc and also the tnm classification of malignant
tumours by the uicc. additionally, there are many other
publications from every organization, like supplements, atlases,
pocket guides, and textbooks on extra prognostic
factors. periodic revisions of tnm classification of malignant
tumours are undertaken, currently on a 7-year cycle. shut collaboration
between these organizations in recent years has
ensured that for all cancer sites, the definitions of tnm are
identical. the 7th edition of each publications was published
in 2009.
the anatomical extent of disease, as described by
tnm, isn't the merely prognostic indicator. several other
such indices are identified. one they is also classified as
“tumor- related” factors, that embody tnm other then additionally other
features like histologic type and grade, “host-related”
factors like gender, age, weight loss, and performance
standing, and “treatment-related” factors like the adequacy
of resection margins, radiotherapy dose, and chemotherapy
response. these is more categorized as those that are
thought of “essential, ” those that offer supplementary
steering by giving “additional” info, and people that
are as nevertheless unproven other then are “new and promising. ” these, for
lung cancer, are depicted in tables thirty. one to thirty. three. two in recent
years, advances in molecular biology have taught us much
concerning the method of carcinogenesis, the genetic basis for
predisposition in bound tumor types, the mechanisms by
that cancers progress and metastasize, and also the reasons for
varying responses to treatment and, in a few cancers, have
provided extra prognostic info. in lung cancer,
as nevertheless, there's no consensus on that molecular markers
are of prognostic importance. three the anatomical extent of
disease, as described by tnm stage, remains the foremost useful
prognostic tool.

Read more →

PATTERNS OF SURGICAL CARE OF LUNG CANCER PATIENTS

REFERENCES
1. Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung
cancer patients. Ann Thorac Surg 2005;80:2051–2056.
2. Osaki T, Oyama T, Gu CD, et al. Prognostic impact of micrometastatic
tumor cells in the lymph nodes and bone marrow of patients with
completely resected stage I non-small-cell lung cancer. J Clin Oncol
2002;20:2930–2936.
3. Wu J, Ohta Y, Minato H, et al. Nodal occult metastasis in patients with
peripheral lung adenocarcinoma of 2.0 cm or less in diameter. Ann
Thorac Surg 2001;71:1772–1777.
4. Maddaus M, Wang X, Vollmer R, et al. CALGB 9761: a prospective
analysis of IHC and PCR based detection of occult metastatic disease
in stage I NSCLC. ASCO Annual Meeting Proceedings Part I, 2006.
J Clin Oncol 2006;24:7030.
5. Detterbeck F, Jantz M, Wallace M, et al. Invasive mediastinal staging of
lung cancer: an ACCP evidence-based clinical practice guideline (2nd
edition). Chest 2007;132:202S–220S.
6. Silvestri G, Gould MK, Margolis ML, et al. Non-invasive staging of
non-small cell lung cancer: ACCP evidenced-based clinical practice
guidelines (2nd edition). Chest 2007;132:178S–201S.
7. Cybulsky IJ, Bennett WF. Mediastinoscopy as a routine outpatient
procedure. Ann Thorac Surg 1994;58:176–178.
8. Vallières E, Pagé A, Verdant A. Ambulatory mediastinoscopy and anterior
mediastinotomy. Ann Thorac Surg 1991;52:1122–1126.
9. Selby JH Jr, Leach CL, Heath BJ, et al. Local anesthesia for mediastinoscopy:
experience with 450 consecutive cases. Am Surg 1978;44:
679–682.
10. Kiser AC, Detterbeck FC. General aspects of surgical treatment. In:
Detterbeck FC, Rivera MP, Socinski MA, et al., eds. Diagnosis and
Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing
Clinician . Philadelphia, PA: WB Saunders, 2001:133–147.
11. Detterbeck FC, Jones DR, Parker LA Jr. Intrathoracic staging. In:
Detterbeck FC, Rivera MP, Socinski MA, et al., eds. Diagnosis and
Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing
Clinician . Philadelphia: WB Saunders, 2001:73–93.
12. Coughlin M, Deslauriers J, Beaulieu M, et al. Role of mediastinoscopy
in pretreatment staging of patients with primary lung cancer. Ann
Thorac Surg 1985;40:556–560.
13. Staples CA, Müller NL, Miller RR, et al. Mediastinal nodes in bronchogenic
carcinoma: comparison between CT and mediastinoscopy.
Radiology 1988;167:367–372.
14. Gdeedo A, Van Schil P, Corthouts B, et al. Prospective evaluation of
computed tomography and mediastinoscopy in mediastinal lymph
node staging. Eur Respir J 1997;10:1547–1551.
15. Van den Bosch JM, Gelissen HJ, Wagenaar SS. Exploratory thoracotomy
in bronchial carcinoma. J Thorac Cardiovasc Surg 1983;85:733–737.
16. Hammoud ZT, Anderson RC, Meyers BF, et al. The current role of mediastinoscopy
in the evaluation of thoracic disease. J Thorac Cardiovasc
Surg 1999;118:894–899.
17. Lardinois D, Schallberger A, Betticher D, et al. Postinduction videomediastinoscopy
is as accurate and safe as video-mediastinoscopy in
patients without pretreatment for potentially operable non-small cell
lung cancer. Ann Thorac Surg 2003;75:1102–1106.
18. Smulders SA, Smeenk FW, Janssen-Heijnen ML, et al. Surgical mediastinal
staging in daily practice. Lung Cancer 2005;47:243–251.
19. Bach PB, Cramer LD, Schrag D, et al. The influence of hospital volume
on survival after resection for lung cancer. N Engl J Med 2001;
345:181–188.
20. Silvestri GA, Handy J, Lackland D, et al. Specialists achieve better outcomes
than generalists for lung cancer surgery. Chest 1998;114:675–680.
21. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or
specialization and outcomes in cancer treatment: importance in quality
of cancer care. J Clin Oncol 2000;18:2327–2340.
22. Detterbeck F. What to do with “surprise” N2: intraoperative management
of patients with non-small cell lung cancer. J Thorac Oncol
2008;3:289–302.
23. Detterbeck F, Falen S, Rivera M, et al. Seeking a home for a PET, part
2: defining the appropriate place for positron emission tomography
imaging in the staging of patients with suspected lung cancer. Chest
2004;125:2300–2308.
24. Gonzalez–Stawinski GV, Lemaire A, Merchant F, et al. A comparative
analysis of positron emission tomography and mediastinoscopy
in staging non-small cell lung cancer. J Thorac Cardiovasc Surg
2003;126:1900–1905.
25. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron
emission tomography and computed tomography for mediastinal
staging in patients with non-small-cell lung cancer: a meta-analysis.
Ann Intern Med 2003;139:879–892.
26. De Leyn P, Lardinois D, Van Schil P, et al. ESTS guidelines for preoperative
lymph node staging for non-small cell lung cancer. Eur J
Cardiothorac Surg 2007;32:1–8.
27. Venissac N, Alifano M, Mouroux J. Video-assisted mediastinoscopy: experience
from 240 consecutive cases. Ann Thorac Surg 2003;76:208–212.
28. Kimura H, Iwai N, Ando S, et al. A prospective study of indications
for mediastinoscopy in lung cancer with CT findings, tumor size, and
tumor markers. Ann Thorac Surg 2003;75:1734–1739.
29. Witte B, Wolf M, Huertgen M, et al. Video-assisted mediastinoscopic
surgery: clinical feasibility and accuracy of mediastinal lymph node
staging. Ann Thorac Surg 2006;82:1821–1827.
30. Leschber G, Holinka G, Linder A. Video-assisted mediastinoscopic
lymphadenectomy (VAMLA):a method for systematic mediastinal
lymph node dissection. Eur J Cardiothorac Surg 2003;24:192–195.
31. Hurtgen M, Friedel G, Toomes H, et al. Radical video-assisted mediastinoscopic
lymphadenectomy (VAMLA):technique and first results.
Eur J Cardiothorac Surg 2002;21:348–351.
32. Zieli´nski M. Transcervical extended mediastinal lymphadenectomy:
results of staging in two hundred fifty-six patients with non-small cell
lung cancer. J Thorac Oncol 2007;2:370–372.
33. Kuzdzal J, Zielinski M, Papla B, et al. Transcervical extended mediastinal
lymphadenectomy—the new operative technique and early results
in lung cancer staging. Eur J Cardiothorac Surg 2005;27:384–390.
34. Kuzdzal J, Zielinski M, Papla B, et al. The transcervical extended mediastinal
lymphadenectomy versus cervical mediastinoscopy in non-small
cell lung cancer staging. Eur J Cardiothorac Surg 2007;31:88–94.
35. Cerfolio RJ, Bryant AS, Eloubeidi MA. Accessing the aortopulmonary
window (#5) and the para-aortic (#6) lymph nodes in patients with
non-small cell lung cancer. Ann Thorac Surg 2007;84:940–945.
36. Sebastian–Quetglas F, Molins L, et al. Clinical value of video-assisted
thoracoscopy for preoperative staging of non-small cell lung cancer: a
prospective study of 105 patients. Lung Cancer 2003;42:297–301.
37. Eggeling S, Martin T, Bottger J, et al. Invasive staging of nonsmall
cell lung cancer: a prospective study. Eur J Cardiothorac Surg
2002;22:679–684.
38. Landreneau RJ, Hazelrigg SR, Mack MJ, et al. Thoracoscopic mediastinal
lymph node sampling: useful for mediastinal lymph node stations
inaccessible by cervical mediastinoscopy. J Thorac Cardiovasc Surg
1993;106:554–558.
39. Massone PP, Lequaglie C, Magnani B, et al. The real impact and usefulness
of video-assisted thoracoscopic surgery in the diagnosis and
therapy of clinical lymphadenopathies of the mediastinum. Ann Surg
Oncol 2003;10:1197–1202.
40. Roberts JR, Blum MG, Arildsen R, et al. Prospective comparison of
radiologic, thoracoscopic, and pathologic staging in patients with early
non-small cell lung cancer. Ann Thorac Surg 1999;68:1154–1158.
41. Detterbeck F. Integration of mediastinal staging techniques for lung
cancer. Semin Thorac Cardiovasc Surg 2007;19:217–224.
42. Boyer M, Viney R, Fulham M, et al. A randomised trial of conventional
staging with or without positron emission tomography (PET) in
patients with stage 1 or 2 non-small cell lung cancer (NSCLC). ASCO
Proc 2001;20:309a.
43. Farrell MA, McAdams HP, Herndon JE, et al. Non-small cell lung
cancer: FDG PET for nodal staging in patients with stage I disease.
Radiology 2000;215:886–890.
44. Leslie A, Jones AJ, Goddard PR. The influence of clinical informa tion on
the reporting of CT by radiologists. Br J Radiol 2000;73:1052–1055.
45. Smulders S, Gundy C, van Lingen A, et al. Observer variation of
2-deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography in
mediastinal staging of non-small cell lung cancer as a function of experience,
and its potential clinical impact. Mol Imaging Biol 2007;9:
318–322.
46. Brehmer B. In one word: not from experience. Acta Psychologica
1980;45:223–241.
47. Serra M, Cirera L, Rami-Porta R, et al. Routine positron emission tomography
(PET) and selective mediastinoscopy is as good as routine
mediastinoscopy to rule out N2 disease in non-small cell lung cancer
(NSCLC). J Clin Oncol 2006;24(No. 18S Part I of II):S371.
48. Cerfolio RJ, Bryant AS, Ojha B, et al. Improving the inaccuracies of
clinical staging of patients with NSCLC: a prospective trial. Ann Thorac
Surg 2005;80:1207–1214.
49. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDGPET
for the management of potentially operable non-small cell lung
cancer; priority for a PET-based strategy after nodal-negative CT results.
Eur J Nucl Med 2000;27:1598–1609.
50. Patterson GA, Piazza D, Pearson FG, et al. Significance of metastatic
disease in subaortic lymph nodes. Ann Thorac Surg 1987;43:155–159.
51. Detterbeck FC, Jones DR. Surgical treatment of stage IIIa (N2)
non-small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski
MA, et al., eds. Diagnosis and Treatment of Lung Cancer: An Evidence-
Based Guide for the Practicing Clinician . Philadelphia: WB Saunders,
2001:244–256.
52. Jiao J, Magistrelli P, Goldstraw P. The value of cervical mediastinoscopy
combined with anterior mediastinotomy in the peroperative evaluation
of bronchogenic carcinoma of the left upper lobe. Eur J Cardiothorac
Surg 1997;11:450–454.
53. Best LA, Munichor M, Ben-Shakhar M, et al. The contribution of anterior
mediastinotomy in the diagnosis and evaluation of diseases of the
mediastinum and lung. Ann Thorac Surg 1987;43:78–81.
54. Ginsberg RJ, Rice TW, Goldberg M, et al. Extended cervical mediastinoscopy:
a single staging procedure for bronchogenic carcinoma of the
left upper lobe. J Thorac Cardiovasc Surg 1987;94:673–678.
55. Freixinet Gilart J, Gámez-Garcia P, Rodríguez de Castro F, et al.
Extended cervical mediastinoscopy in the staging of bronchogenic carcinoma.
Ann Thorac Surg 2000;70:1641–1643.
56. Urschel JD, Vretenar DF, Dickout WJ, et al. Cerebrovascular accident
complicating extended cervical mediastinoscopy. Ann Thorac Surg
1994;57:740–741.
57. Lopez L, Varela A, Freixinet J, et al. Extended cervical mediastinoscopy:
prospective study of fifty cases. Ann Thorac Surg 1994;57:555–558.
58. Ginsberg RJ. In discussion of: Lopez L, Varela A, Freixinet J, et al.
Extended cervical mediastinoscopy: prospective study of fifty cases.
Ann Thorac Surg 1994;57:557–558.
59. Scott W, Howington J, Feigenberg S, et al. Treatment of non-small
cell lung cancer - stage I & II: ACCP evidence-based clinical practice
guideline (2nd ed). Chest 2007;132:234S–242S
60. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative
lymph node staging in non-small cell lung cancer. Eur J
Cardiothorac Surg 2006;30:787–792.
61. Bollen EC, van Duin CJ, Theunissen PH, et al. Mediastinal lymph
node dissection in resected lung cancer: morbidity and accuracy of
staging. Ann Thorac Surg 1993;55:961–966.
62. Gaer JA, Goldstraw P. Intraoperative assessment of nodal staging at
thoracotomy for carcinoma of the bronchus. Eur J Cardiothorac Surg
1990;4:207–210.
63. Wu Y, Huang ZF, Wang SY, et al. A randomized trial of systematic
nodal dissection in resectable non-small cell lung cancer. Lung Cancer
2002;36:1–6.
64. Izbicki JR, Passlick B, Karg O, et al. Impact on radical systematic mediastinal
lymphadenectomy on tumor staging in lung cancer. Ann
Thorac Surg 1995;59:209–214.
65. Allen MS, Darling GE, Pechet TT, et al. Morbidity and mortality of
major pulmonary resections in patients with early-stage lung cancer:
initial results of the randomized, prospective ACOSOG Z0030 Trial.
Ann Thorac Surg 2006;81:1013–1020.
66. Magnanelli G, Scanagatta P, Benato C, et al. Is sampling really effective
in staging non-small cell lung cancer? A prospective study. Chir Ital
2006;58:19–22.
67. Keller SM, Adak S, Wagner H, et al. Mediastinal lymph node dissection
improves survival in patients with stages II and IIIa non-small
cell lung cancer; from the Eastern Cooperative Oncology Group. Ann
Thorac Surg 2000;70:358–365.
68. Sugi K, Nawata K, Fujita N, et al. Systematic lymph node dissection
for clinically diagnosed peripheral non-small-cell lung cancer less than
2 cm in diameter. World J Surg 1998;22:290–294.
69. Izbicki JR, Thetter O, Habekost M, et al. Radical systematic mediastinal
lymphadenectomy in non-small cell lung cancer: a randomized
controlled trial. Br J Surg 1994;81:229–235.
70. Funatsu T, Matsubara Y, Ikeda S, et al. Preoperative mediastinoscopic
assessment of N factors and the need for mediastinal lymph node dissection
in T1 lung cancer. J Thorac Cardiovasc Surg 1994;108:321–328.
71. Luke WP, Pearson FG, Todd TR, et al. Prospective evaluation of mediastinoscopy
for assessment of carcinoma of the lung. J Thorac Cardiovasc
Surg 1986;91:53–56.
72. De Leyn P, Schoonooghe P, Deneffe G, et al. Surgery for non-small cell
lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal
nodes (N2 disease). Eur J Cardiothorac Surg 1996;10:649–655.
73. Brion JP, Depauw L, Kuhn G, et al. Role of computed tomography and
mediastinoscopy in preoperative staging of lung carcinoma. J Computer
Assist Tomogr 1985;9:480–484.
74. Jolly PC, Hutchinson CH, Detterbeck F, et al. Routine computed tomographic
scans, selective mediastinoscopy, and other factors in evaluation
of lung cancer. J Thorac Cardiovasc Surg 1991;102:266–271.
75. Ratto GB, Frola C, Cantoni S, et al. Improving clinical efficacy of
computed tomographic scan in the preoperative assessment of patients
with non-small cell lung cancer. J Thorac Cardiovasc Surg 1990;
99:416–425.
76. Ebner H, Marra A, Butturini E, et al. Clinical value of cervical mediastinoscopy
in the staging of bronchial carcinoma. Ann Ital Chir
1999;70:873–879.
77. Deneffe G, Lacquet L, Gyselen A. Cervical mediastinoscopy and anterior
mediastinotomy in patients with lung cancer and radiologically
normal mediastinum. Eur J Respir Dis 1983;64:613–619.
78. Aaby C, Kristensen S, Nielsen SM. Mediastinal staging of non-smallcell
lung cancer: computed tomography and cervical mediastinoscopy.
ORL J Otorhinolaryngol Relat Spec 1995;57:279–285.
79. Page A, Nakhle G, Mercier C, et al. Surgical treatment of bronchogenic
carcinoma: the importance of staging in evaluating late survival. Ca J
Surg 1987;30:96–99.
80. Dillemans B, Deneffe G, Verschakelen J, et al. Value of computed tomography
and mediastinoscopy in preoperative evaluation of mediastinal
nodes in non-small cell lung cancer: a study of 569 patients. Eur J
Cardiothorac Surg 1994;8:37–42.
81. Riordan D, Buckley D, Aherne T. Mediastinoscopy as a predictor of
resectability in patients with bronchogenic carcinoma. Ir J Med Sci
1997;160:291–292.
82. Choi YS, Shim YM, Kim J, et al. Mediastinoscopy in patients with clinical
stage I non-small cell lung cancer. Ann Thorac Surg 2003;75:364–366.
83. Gürses A, Turna A, Bedirhan M, et al. The value of mediastinoscopy
in preoperative evaluation of mediastinal involvement in non-small-cell
lung cancer patients with clinical NO disease. Thorac Cardiovasc Surg
2002;50:174–177.

Read more →

VIDEOMEDIASTINOSCOPY OR TRANSCERVICAL MEDIASTINAL LYMPHADENECTOMY ARE SAFE

Surgical analysis of the mediastinum has evolved, and newer
techniques like videomediastinoscopy or transcervical mediastinal
lymphadenectomy are safe and additional correct than
ancient mediastinoscopy. at a similar time, nonsurgical,
needle-based techniques like eus-na and ebus-na have
been developed. the sensitivity of those techniques is fairly
similar, however the needle-based techniques have the next fn rate
that limits their utility, particularly in patients with normal-sized
mediastinal nodes.
the quality of surgical staging preoperatively may be a major
issue, and that it seems that the distinction between high- and
poor-quality staging is seemingly to be a lot of larger than differences
between numerous surgical and nonsurgical techniques. invasive
mediastinal staging remains vital in several patients with
lung cancer. careful attention to mediastinal staging is crucial
and, ideally, ought to be addressed in a very multidisciplinary fashion.

Read more →

INTRAOPERATIVE SURGICAL STAGING

Intraoperative surgical staging
resection of a lung cancer includes a thorough assessment of
hilar and mediastinal lymph nodes, and something but
this constitutes a substandard operation. 59, sixty it's important
to recognize the differences between a selective node sampling
( limited sampling directed by “judgment” ), a systematic sampling
( a minimum of one representative node from every ipsilateral
mediastinal station ), an entire mediastinal lymph node dissection
( lnd, removal of all ipsilateral nodal tissue ), and a
lobe-specific node operation ( removal of all nodal tissue within the
mediastinal node stations most commonly affected for that
lobe ). either a systematic sampling or an entire node dissection
ought to be done, though a lobe- specific systematic node
operation is also appropriate in a few circumstances. 60
many randomized and controlled studies have demonstrated
that systematic sampling or node operation provides
additional correct staging data than a selective-node sampling.
61–63 stage classification is constant when systematic
mediastinal node sampling versus a formal lymph node operation.
61, 64–66 there's no increase in morbidity or mortality
when lnd. sixty five as a result of adjuvant therapy is recommended
for patients with nodal involvement, an operation that omits
a thorough nodal assessment should be condemned as being of
unacceptable quality. this can be true whether or not the procedure is performed
via thoracotomy or thoracoscopy, and applies to sublobar
resection furthermore.
whether or not there's a therapeutic profit to an entire lymph
node operation is controversial. 63, 67–69 2 randomized studies
have found no differences in recurrence rates or survival
in patients undergoing lnd versus systematic lymph node
sampling ( in 115 patients with 2-cm pathologic stage i pi
nsclc and 182 ci to iiia patients ). 68, 69 another randomized
study found a profit to lnd as compared with selective sampling,
though this was potentially confounded by higher staging
when lnd. 63 finally, 2 retrospective studies have found
conflicting results. 67, 70 the long-term survival results of the
completed yankee school of surgeons oncology group
randomized trial of mediastinal node operation ( acosog
z0030 ) aren't nevertheless on the market

Read more →

INTEGRATION OF INVASIVE STAGING TECHNIQUES

The varied techniques of tissue staging ought to be viewed as
complementary and not as competitive procedures. forty one there
are several reasons for this. 1st of all, one can't compare
the performance characteristics ( sensitivity, specificity, and
fn and fp rates ) of 2 tests unless they're being applied
to a similar patient population. five it's quite clear that in most
printed studies, the patient populations included don't seem to be
a similar. they differ relative to whether or not lymph nodes were
enlarged or normal sized, that node stations were most
s uspicious, and whether or not the issue at hand was merely to establish
a diagnosis or to establish a tissue stage. furthermore,
in a very ssessing the r esults of a localityicular technique, it's important
to r ecognize that the performance characteristics are
d ifferent in patients with enlarged or normal-sized mediastinal
nodes. one mustn't use information from patients with enlarged
nodes to e stimate the price of a take a look at for a patient with
n ormal-sized nodes. so, patient characteristics are important
d eterminants in choice of the simplest technique of tissue
staging.
the results of staging procedures are conjointly strongly affected
by the expertise of the physicians performing the take a look at. it's likely
that the distinction between a similar procedure performed by
an professional with a dedicated interest and a fewone who performs
the procedure solely often is so much bigger than differences
between completely different tests. so, appropriate integration of
staging procedures is dependent on the native expertise. this
should be evaluated critically, ideally in a very multidisciplinary manner
and based mostly on actual native information.
a advised algorithm ( table 29. three ) is to perform mediastinoscopy
because the typically preferred tissue staging technique in
patients with normal-sized mediastinal nodes ( e. g., in patients
with a central tumor or n1 node enlargement who have a 20%
to 25% incidence of n2 involvement ). this can be as a result of the primary
issue is to rule out node involvement, and needle-based
techniques carry a high fn rate, particularly in normal-sized
nodes. as a result of a negative needle biopsy ( eus-na, ebusna,
or tbna ) ought to be followed by a mediastinoscopy, most
patients would endure each tests if a needle technique is employed
because the 1st step. on the opposite hand, a needle-based approach
could also be an honest 1st step in patients with enlarged nodes, because
it's going to spare several patients the would like on behalf of mediastinoscopy ;
but, a negative needle take a look at in patients with enlarged
nodes ought to typically still be followed by a mediastinoscopy.
in fact, these recommendations are affected by the locations
of the nodes that are most in question further because the local
expertise, as previously discussed.

Read more →

LEFT UPPER LOBE TUMORS AND AORTOPULMONARY WINDOW NODES

Left higher lobe tumors and aortopulmonary window nodes
cancers within the left higher lobe ( lul ) have a predilection for
involvement of the nodes within the apw ( station five ). these nodes
are classified as mediastinal nodes and represent the foremost important
cluster of n2 nodes that aren't accessible by standard
cervical mediastinoscopy. it's been instructed that nodes in
this region shouldn't be viewed as mediastinal nodes and
that resection of patients ought to be performed regardless of
apw node involvement, creating assessment of those nodes
superfluous. 50 this was based mostly on a selected subgroup of 23
utterly resected patients who had apw node involvement
because the merely website of n2 disease. though, analysis of all of the
knowledge during this regard shows that survival of patients with only
apw node involvement isn't substantially totally different than that
of patients with involvement of merely one n2 node station
in an exceedinglynother location. 22, 51 so, the issue is additional a matter
of whether or not patients with involvement of one mediastinal
node station ought to bear surgical resection and not
whether or not apw nodes ought to be classified as n2 nodes.
the classic means of invasively assessing this space may be a
chamberlain procedure ( additionally called an anterior mediastinotomy ),
that involves an incision within the second or third
intercostal area barely to the left of the sternum. traditionally,
an overnight hospital keep was necessary, however in several establishments,
this can be now not found to be necessary, particularly as
surgeons have used visualization between the ribs additional frequently
as opposed to removal of a priceal cartilage. the reliability
of this procedure has not been extensively documented,
despite its common use. the sensitivity of a chamberlain
procedure in an exceedinglyddition to a regular cervical mediastinoscopy
in patients with lul tumors may be approximately 87%, and also the
fn rate may be approximately 10%. five these patients are primarily
from radiographic cluster b, with in all probability many from group
c. 2 further studies concerning this procedure don't have anyt
very addressed the reliability of the procedure for staging of
nsclc. in one study, no actual biopsies were performed in
most patients, and also the procedure was used to assess resectability
( resectable patients included those with bulky apw nodal
involvement during this series ). 52 the opposite study used anterior
mediastinotomy primarily for diagnosis ( not staging ), and
included pulmonary biopsies and analysis of patients with
mediastinal masses. 53 indeed, merely many patients included in
this study had lung cancer.
extended cervical mediastinoscopy offers an alternative
means of invasive assessment of apw nodes, however is employed in only
many establishments. five with this procedure, a mediastinoscope is
inserted through the suprasternal notch and directed lateral to
the aortic arch. 54 in 100 consecutive patients with lul cancers,
customary mediastinoscopy and extended mediastinoscopy
were found to own a sensitivity of 69% and an fn rate of
11% for detection of n2, n3 disease ( prevalence, 29% ). 54
similar results ( sensitivity, 81% ; fn rate, 9% ) were reported
in an exceedinglynother series of 93 such patients, all of whom had enlarged
apw nodes. fifty five these patients are primarily from radiographic
cluster b, with in all probability many from cluster c. in an exceedinglypproximately
550 patients undergoing extended cervical mediastinoscopy,
2 major complications ( one stroke and one aortic injury )
are reported. 54–58
thoracoscopy has been used to assess apw lymph
nodes. five, 35 the merely study specifically addressing this techniques
found complete accuracy in 39 patients. 35 though, the
study is limited as a result of it concerned merely 3 patients without
station five or six node involvement. eus-na additionally provides an
various methodology of sampling apw nodes ( see previous discussion ).
merely one study has specifically addressed eus-na
for stations five and six, however the knowledge reported don't enable calculation
of sensitivity, specificity, and fn or fp rates. though, a
high fn rate is instructed. 35
in conclusion, it seems that the sensitivity of either a
chamberlain or vats assessment of the apw is high, whereas
the results for extended cervical mediastinoscopy, and perhaps
additionally eus-na, are somewhat lower. the fn rate appears
to be low for all procedures with the exception of eus-na.
though, these conclusions are somewhat speculative because
the number of knowledge offered is limited.

Read more →

WHEN IS TISSUE STAGING NECESSARY ?

Tissue staging of the mediastinum is clearly required if there
is pet activity in mediastinal nodes ( unless there's extensive
mediastinal infiltration ). this is often as a result of the fp rate of pet in
the mediastinum could be approximately 15% to twenty%, five, 25 although
the massivest and most recent metaanalysis found an average fp
rate of 27% ( on a per patient basis, excluding studies with a
prevalence of 10% ). six these recommendations are summarized
in table 29. three.
tissue staging is an elementicularly vital with increasing
wide variability within the quality of pet scans. furthermore,
the accuracy of the scan interpretation is increasingly a difficulty
with the movement to bring pet scanners out into smaller
communities ( particularly mobile scanners ), that hampers
communication between the reader of the pet scan and a physician
experienced in treating lung cancer. there are knowledge that
the interpretation of a ct scan is far more correct when it
is done with input from the treating clinician, 44 and also there are
multiple reasons that would recommend that this is often even a lot of true
with pet ima ging. vital aspects during this regard include
a mechanism on behalf of meaningful interaction between a dedicated
pet radiologist and a clinician with expertise in lung cancer
( enabling collective judgment ) still as a mechanism for
feedback of final results to the radiologist. 45, forty six very little formal
study of those problems has been done, other then they recommend that one
ought to be cautious concerning merely accepting pet interpretation
while not tissue confirmation, particularly when the pet is done
in a very smaller center.
tissue staging of the mediastinum could be also required within the
face of a negative pet within the mediastinum in patients with
discrete mediastinal node involvement ( radiographic cluster b )
and that in patients with central tumors or n1 node enlargement
( radiographic cluster c, fig. 29. one ). five the premise for this statement
is that the finding of an fn rate of pet of approximately
25% within these things. five, 25, 47–49 ct alone could be also notoriously
inaccurate within these patient cohorts ( an fp rate of 40% with
discrete mediastinal node involvement and an fn rate of 25%
in patients with central tumors of n1 node enlargement ). 11
so, tissue staging is necessary in such patients whether
or not a pet is performed.
it's worth noting that correct mediastinal staging is
vital whenever treatment with curative intent is being
planned, not just when the treatment involves operation. the
principles of correct staging are specific to the disease and
to not the modality used. so, a similar knowledge and, so,
a similar rules concerning the want for tissue staging of the mediastinum
apply if the curative treatment being thought-about is
chemoradiation alone, radiofrequency ablation, or stereotactic
radiosurgery

Read more →

WHEN IS TISSUE STAGING NOT REQUIRED ?

When is tissue staging not required ?
tissue confirmation of the mediastinal stage isn't required in
patients with sclc, stage iv nsclc, or malignant pleural
effusion. five within these patients, the standing of the mediastinum is
irrelevant to defining the appropriate treatment. in patients
with in depth mediastinal infiltration ( radiographic cluster a,
fig. 29. one ), the radiographic stage is widely accepted as accurate
while not tissue confirmation. five it should be acknowledged that
this is predicated on general clinical expertise, as a result of there's no
revealed information to prove this. these recommendations are summarized
in table 29. three.
tissue confirmation of the mediastinal stage is unnecessary
in patients with ci tumors based mostly on a chest ct and a
clinical analysis ( i. e., history and physical examination ) ( radiographic
cluster d, fig. 29. one ). five this is predicated on extensive
information that n2 node involvement ( as assessed at thoracotomy ) is
found in 10% of such patients. five the prospect of creating the
diagnosis of n2 involvement by preoperative invasive staging
is lower, as a result of the sensitivity of those tests isn't excellent.
a pet scan to evaluate the mediastinum additionally seems to not
be required in patients with ci tumors. six, 23, 42, forty three this is often because
the prospect of finding a pet-positive n2 nodal metastasis is
5%. 23, forty three in reality, there's a better likelihood of being misled by
pet ( fp mediastinal uptake or fp distant web site of uptake ) than
the prospect of correctly identifying disease spread in patients
with ci tumors.

Read more →

NONSURGICAL INVASIVE TECHNIQUES

Nonsurgical invasive techniques
Many newer techniques of invasive staging that are nonsurgical are on the market,
as well as esophageal ultrasound ( eus ) and endobronchial
ultrasound ( ebus ) coupled with needle aspiration. a full
discussion of those is beyond the scope of this chapter, other then one
can't discus surgical staging in a very vacuum. details of ebus
are discussed in chapter twenty eight. a summary of the performance
characteristics of those newer tests, taken from a systematic review,
five is provided in table 29. two. it should be emphasized that
a direct comparison between totally different techniques is inappropriate
owing to differences within the patient population, both
in terms of the radiographic teams also because the location of
suspicious lymph nodes.
like mediastinoscopy, these needle techniques generally
don't need hospitalization, other then in contrast to mediastinoscopy
they're typically performed no more than with sedation ( not
general anesthesia ). five so, these procedures have an advantage
of being less invasive and advanced. unfortunately, the needlebased
techniques carry an fn rate of approximately 20% to
25%. the sensitivity of a conventional ( non–image guided )
tbna is lower ( around 75% ) than ancient mediastinoscopy,
albeit this has been done nearly completely in
patients with markedly enlarged nodes. five the sensitivity of
eus ( too primarily in enlarged nodes ) is similar to traditional
mediastinoscopy. five on the opposite hand, ebus seems to own
a better sensitivity ( around 90% ) and has been used in both
enlarged and normal-sized nodes.
the major limitation of needle-based techniques is that the
fn rate ( concerning 20% to 25%, seemingly even higher in normalsized
nodes ). in general, a negative eus, ebus, or tbna
ought to be followed by a mediastinoscopy. five so, these techniques
are less useful in patients with normal-sized mediastinal
nodes. this is often each as a result of in general, the sensitivity of
the needle techniques is lower in patients with normal-sized
nodes ( as is additionally in mediastinoscopy ) and a negative result is
a lot of seemingly, other then is relatively unreliable ( owing to the high
fn rate ).
the numerous surgical and nonsurgical invasive staging techniques
ought to be viewed as complimentary. forty one furthermore,
all of the techniques rely on the talent of the operator. the
results revealed from the most effective centers with a dedicated interest
in a localityicular technique can't usually be duplicated more
broadly. the presence of a dedicated interest and expertise with
a localityicular take a look at could also be a key think about determining the most effective
thanks to integrate the numerous staging techniques in a localityicular
institution. ideally, the performance characteristics of staging
tests at a localityicular institution ought to be collected and assessed
to own a sound basis for creating these selections.

Read more →